The Clorox Company (CLX) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of The Clorox Company stock $74.29, price $99.70, that is 25.5% below the price, quality 55 out of 100. Rating: overvalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.
How to read this chart
60‑month range $80.41 – $159.79 · fair‑value band $48.99 – $102.61 · the $99.70 price screens above the $74.29 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.
Follow The Clorox in your weekly email
Every Wednesday you see whether The Clorox is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
The Clorox Company manufactures and markets consumer and professional products worldwide. The company operates through four segments: Health and Wellness, Household, Lifestyle, and International.
Show moreShow less
The Health and Wellness segment offers home care cleaning and disinfecting products, bleach, clog removers, and laundry additives under the Clorox, Clorox2, Pine-Sol, Scentiva, Tilex, Liquid-Plumr, Poett, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand in the United States.
The Household segment provides cat litter products under the Fresh Step and Scoop Away brands; bags and wraps under the Glad brand; and grilling products under the Kingsford brand in the United States.
The Lifestyle segment offers dressings, dips, seasonings, and sauces primarily under the Hidden Valley brand; water-filtration products under the Brita brand; and natural personal care products under the Burt's Bees brand in the United States.
The International segment provides laundry additives, home care products, bags and wraps, cat litter products, water-filtration systems, professional cleaning and disinfecting products, natural personal care products, food, grilling products, and digestive health products internationally primarily under the Clorox, Glad, Poett, Brita, Burt's Bees, Pine-Sol, Ever Clean, Clorinda, Chux and Fresh Step Brands.
It also offers vitamins, minerals, and supplement products under the Natural Vitality, RenewLife, NeoCell, and Rainbow Light brands.
The company sells its products through mass retailers; grocery outlets; warehouse clubs; dollar stores; home hardware centers; drug, pet, and military stores; third-party and owned e-commerce channels; and distributors, as well as a direct sales force.
The company was founded in 1913 and is headquartered in Oakland, California.
Stock analysis
The Clorox Company (CLX) currently trades at $99.70, while our model-based Fair Value estimate is $74.29, 25% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $101.93 per share, and 7 of the 22 models we run sit above the $99.70 price.
Bear case: the Growth DCF group reads lowest at $39.50, and 15 of the 22 models stay below the price. Data coverage for this calculation is high.
Scenario range: $48.99 (bear) to $102.61 (bull), the price of $99.70 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
The Clorox Company reported revenue of $6.7B in FY2026 versus $7.1B in FY2022, a compound −1.4%/yr. Reported net income was $587M in FY2026, compounding +6.2%/yr from FY2022.
Key figures
Market cap $12.2B Large · P/E ratio 17.9 · P/S ratio 1.81 · EPS (TTM) $5.56 · Dividend yield 5.0% · Net margin 8.7% · Return on equity 164% · Return on assets (EBIT) 16.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 65 out of 100 (low confidence).
What moves the price
The share trades about 21% below its 52-week high and 24% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −24% fair-value upside, at −25%, CLX screens richer than that median.
Fair Value models
Bear$48.99Fair Value $74.29Bull$102.61
Price $99.70 · Downside -25.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 4 months old). Earnings retained since then ($0.2085 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director bought shares worth $400,251, on Nov 4, 2026.
BuyPierre R BreberDirector3× since Nov 21, 2025: 13,000 shares, avg. $95.84$1.2MNov 4, 2026
Plus 20 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.8%
Start year 2021 (pandemic). Over 10 years: +1.6% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−3.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.2%
Dividend (yield on the price)5.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−2.9% vs −0.2%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 17%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+19.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +16.3% a year for the price and +2.0% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Brand-driven durability provides moderate stability, yet thin innovation signals and elevated leverage from acquisitions remain the core limitations.
Main risk: Private-label brands and competitors such as Procter & Gamble and Reckitt could capture more shelf space with lower-priced alternatives, pressuring Clorox's volumes and margins in household cleaning categories.
Bull case: Clorox could leverage its brand strength and agile innovation systems to develop differentiated eco-friendly or concentrated formats that appeal to value-conscious consumers and reduce reliance on traditional retail channels.
Bear case: Intensified private-label competition combined with ongoing regulatory scrutiny could erode market share in core cleaning categories and increase costs, limiting the company's ability to invest in growth.
Clorox posted stronger-than-expected first-quarter results thanks to the Gojo acquisition and productivity gains, yet it lifted its inflation outlook by forty million dollars and now sees full-year earnings near the bottom of its prior range. The same deal has also pushed debt and interest costs higher. Will the cost savings and synergies ultimately shield margins from these pressures, or will elevated input costs continue to limit cash generation?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 234 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score55 · Below median
Fair Value upside−25.5% · Below median
Profitability
Return on equity (12 months)163.8% · Top 25%
Return on assets7.5% · Above median
Net margin (12 months)8.7% · Above median
Operating margin (12 months)12.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)−2.0% · Below median
Dividend yield (12 months)5.0% · Top 25%
Balance sheet
Debt / equity44.23× · Highest 25%
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/E (12 months)17.9× · Pricier than median
P/S (12 months)1.81× · Pricier than median
Price / free cash flow30.1× · Priciest 25%
EV/EBITDA14.1× · Pricier than median
PEG1.10× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)0· sector 22
PAST (return on equity)100· sector 29
HEALTH (low debt)0· sector 98
DIVIDEND (yield)100· sector 53
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "The Clorox Company Fair Value". https://www.fairvalue-calculator.com/stock/CLX
Frequently asked questions
Is The Clorox Company (CLX) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $74.29 versus a price of $99.70, about 25% lower (overvalued).
What is the fair value of CLX?
Our model-based fair value for The Clorox Company is $74.29 (as of Nov 4, 2026), built from audited fundamentals. The current price: $99.70.
What is the quality score of CLX?
The Clorox Company has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for The Clorox Company (CLX)?
Our model-based price target is the fair value of $74.29 (as of Nov 4, 2026) from 22 valuation models. Cautious scenario $48.99, optimistic scenario $102.61. It is a calculation from audited fundamentals, not an analyst target.
What is the The Clorox Company stock forecast for 2026?
Our models put fair value at $74.29, about 25% lower versus a price of $99.70 (overvalued). Cautious scenario $48.99, optimistic scenario $102.61. The calculation is refreshed regularly with new filings.
What is the revenue of The Clorox Company (CLX)?
The Clorox Company reported trailing-twelve-month revenue of about $6.7B (latest available figure, as of Nov 4, 2026).
Does The Clorox Company pay a dividend?
The Clorox Company currently shows a dividend yield of 4.98% relative to its recent price (as of Nov 4, 2026).
What growth is priced into The Clorox Company (CLX)?
For today's price to be fair in a discounted-cash-flow model, The Clorox Company would have to grow free cash flow by +19.1 % per year for five years (discount rate 8.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.8 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of CLX use?
Our models discount The Clorox Company at 8.3 %: a base by market capitalisation (large), damped by beta 0.58, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For The Clorox Company that is +19.1 % per year a year over ten years, using the same discount rate (8.3 %) and the same formula as our fair value.
How much growth has The Clorox Company (CLX) delivered so far?
Over the past 5 years revenue at The Clorox Company grew -1.8 % a year. The price currently implies +19.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of The Clorox Company (CLX) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into The Clorox Company (+19.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of The Clorox Company (CLX)?
The free-cash-flow yield on the price is 3.33 %: that much free cash flow The Clorox Company produces per unit of market value. When it exceeds the discount rate of our models (8.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of The Clorox Company (CLX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For The Clorox Company it is $74.29 per share (as of Nov 4, 2026), against a price of $99.70. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is The Clorox Company stock overvalued or undervalued in 2026?
As of Nov 4, 2026, CLX trades above its calculated fair value: price $99.70, fair value $74.29, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CLX?
No. The price is what the market pays today ($99.70); the fair value is what the company's own numbers justify ($74.29). For The Clorox Company the two are $25.41 per share apart. That gap is exactly why we show both numbers side by side.
How much is The Clorox Company worth?
The market values The Clorox Company at about $12.2B (market capitalisation, as of Nov 4, 2026). Per share that is $99.70; our models calculate a fair value of $74.29 per share.
What do the bullish and bearish scenarios say about CLX?
Our models span a range for The Clorox Company: cautious scenario $48.99, base $74.29, optimistic $102.61 per share (as of Nov 4, 2026, price $99.70). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CLX?
The Clorox Company trades at a price-to-earnings ratio of 17.9 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $74.29 is built from several models across several years. Excluding one-off items of fiscal year 2026 it is 18.0 (reported for FY2026: 20.7). Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings, 6 of the years ex one-offs: 24.4. Other multiples: PEG 1.1, P/S 1.8, EV/EBITDA 14.1.
What is the PEG ratio of CLX?
The PEG ratio of The Clorox Company is 1.10 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of The Clorox Company (CLX)?
Balance-sheet figures for The Clorox Company (as of Nov 4, 2026): return on equity 163.8%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is CLX from its 52-week high?
The Clorox Company trades at $99.70, about 21% below its 52-week high of $125.58 and 24% above the low of $80.41 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $74.29 is for.
Which stocks are comparable to The Clorox Company?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Kimberly-Clark Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is The Clorox Company stock attractive at the current price?
The data as of Nov 4, 2026: price $99.70, calculated fair value $74.29 (−25%), Quality Score 55/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CLX calculated?
We run The Clorox Company through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $74.29, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. The Clorox Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of The Clorox Company (CLX)?
The closing price on Nov 5, 2026 was $99.70. Our model-based fair value is $74.29, about 25% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with The Clorox Company right now?
Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($48.99 to $102.61) leaves room in how you read the outcome.
Where does the earnings growth of The Clorox Company (CLX) come from?
Earnings per share at The Clorox Company grew −0.8 % a year from 2015 to 2026. Broken into its drivers: revenue per share +2.8 %, EBIT margin −0.8 %, tax rate +1.4 %, residual (interest, one-offs) −4.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of The Clorox Company
How large is the market capitalisation of The Clorox Company (CLX)?
The market capitalisation of The Clorox Company is $12.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of The Clorox Company (CLX)?
The price-to-sales ratio of The Clorox Company is 1.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of The Clorox Company (CLX)?
Earnings per share at The Clorox Company are $5.56 (price ÷ EPS = P/E 17.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of The Clorox Company (CLX)?
The dividend yield of The Clorox Company is 5.0% (payout 77.8%, on adjusted earnings, reported 89.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of The Clorox Company (CLX)?
The net margin of The Clorox Company is 8.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of The Clorox Company (CLX)?
The return on equity (ROE) of The Clorox Company is 164% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of The Clorox Company (CLX)?
On an EBIT basis the return on assets of The Clorox Company is 16.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of The Clorox Company (CLX)?
The operating margin of The Clorox Company is 12.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at The Clorox Company (CLX)?
Revenue at The Clorox Company is growing −2.0% versus a year earlier (3y avg −3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at The Clorox Company (CLX)?
Earnings per share at The Clorox Company are growing −50.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does The Clorox Company (CLX) carry?
The net debt of The Clorox Company is $5.4B (fiscal year 2026, ≈ 13.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch The Clorox Company in the live analysis
One click puts The Clorox Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 4, 2026